The effect of the secondary bile acid glycodeoxycholic acid as a therapy for diabetes.
Recruiting
- Conditions
- type 2 diabetes mellitus
- Registration Number
- NL-OMON20316
- Lead Sponsor
- Academic Medical Center (AMC), Amsterdam, The Nettherlands
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
Exclusion Criteria
•Use of medication that interferes with BA metabolism (colesevelam, colestimide, ursodeoxycholic acid).
•Diabetes treatment with dipeptidyl peptidase-4 inhibitors, GLP-1 receptor agonists or insulin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Secretion of GLP-1 and insulin, postprandial inflammation and postprandial hyperlipidemia. THe primary objective of phase 1 is to determine safety of long-term gDCA administration in healthy volunteers.
- Secondary Outcome Measures
Name Time Method The effect of gDCA administration on bile acid metabolism, glucoregulatory and gut hormones, resting energy expenditure, microbiome, appetite and satiety, cholesterol elimination.